Immunotherapy for glioblastoma: playing chess, not checkers
CM Jackson, M Lim - Clinical Cancer Research, 2018 - AACR
CM Jackson, M Lim
Clinical Cancer Research, 2018•AACRPatients with glioblastoma (GBM) exhibit a complex state of immune dysfunction involving
multiple mechanisms of local, regional, and systemic immunosuppression and tolerance.
These pathways are now being identified and their relative contributions explored.
Delineating how these pathways are interrelated is paramount to effectively implementing
immunotherapy for GBM. Clin Cancer Res; 24 (17); 4059–61.© 2018 AACR. See related
articles by Woroniecka et al., p. 4175 and Mohme et al., p. 4187
multiple mechanisms of local, regional, and systemic immunosuppression and tolerance.
These pathways are now being identified and their relative contributions explored.
Delineating how these pathways are interrelated is paramount to effectively implementing
immunotherapy for GBM. Clin Cancer Res; 24 (17); 4059–61.© 2018 AACR. See related
articles by Woroniecka et al., p. 4175 and Mohme et al., p. 4187
Abstract
Patients with glioblastoma (GBM) exhibit a complex state of immune dysfunction involving multiple mechanisms of local, regional, and systemic immunosuppression and tolerance. These pathways are now being identified and their relative contributions explored. Delineating how these pathways are interrelated is paramount to effectively implementing immunotherapy for GBM. Clin Cancer Res; 24(17); 4059–61. ©2018 AACR.
See related articles by Woroniecka et al., p. 4175 and Mohme et al., p. 4187
AACR